

Zambia Support for Rotavirus Vaccine

This Decision Letter sets out the Programme Terms of a Programme.

 Grant number: 1821-ZMB-13b-X; 13-ZMB-08a-Y Date of Decision Letter: 22 December 2017 Date of the Partnership Framework Agreement: 22 October 2014 Programme title: New Vaccine Support (NVS), Rotavirus Routine 	1.	. Country: Zambia										
4. Date of the Partnership Framework Agreement: 22 October 2014	2.	Grant number: 1821-ZMB-13b-X; 13-ZMB-08a-Y										
	3.	Date of Decision Letter: 22 December 2017										
5. Programme title: New Vaccine Support (NVS), Rotavirus Routine	4.	Date of the Partnership Framework Agreement: 22 October 2014										
- · · · · /·	5.											
6. Vaccine type: Rotavirus												
 Requested product presentation and formulation of vaccine: Rotavirus, 2 dose(s) schedule 	7.											
8. Programme duration ¹ : 2013 - 2021												
 Programme Budget (indicative): (subject to the terms of the Partnership Framework Agreement 												
								Total ²				
	Budge	et						US\$ 22,616,615				
 10. Vaccine introduction grant (in US\$): Vaccine introduction grant of US\$567,000 disbursed on 20 September 2013. Return of unused funds of US\$14,232 on 04 Febru 2016. 11. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement)⁴ 		disburs 2016. Indicat	ed on 20 Septe	mber 2013.	Return of unu	ised funds of	US\$14,232	on 04 February				
Type of supplies to be purchased2013-20172018with Gavi funds in each year		2018										
	Numb	1,482,000										
Annual Amounts (US\$) US\$11,282,115 ⁵ US\$3,082,000	Annua	al Amou	nts (US\$)		US\$11,282,115 ⁵ US\$3,082,000		\$\$3,082,000					
 12. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF. 13. Self-procurement: Not applicable 												

¹ This is the entire duration of the Programme.

² This is the total amount endorsed by Gavi for the entire duration of the Programme.

³ This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

⁴ This is the amount that Gavi has approved.

⁵ This is the consolidated amount for all previously approved years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.



14. Co-financing obligations: Reference code: 1821-ZMB-13b-X-C

According to the co-financing policy, the Country falls within the group Preparatory transition.

The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

2018	2019	2020	2021
256,500	268,500	316,500	385,500
US\$513,360			
US\$530,500	US\$556,000	US\$657,500	US\$800,000
	256,500 US\$513,360	256,500 268,500 US\$513,360	256,500 268,500 316,500 US\$513,360

15. Operational support for campaigns: Not applicable

16. Additional reporting requirements:

Reports and other information	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	Мау
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat

17. Financial clarifications: Not applicable

18. Other conditions:

The country is reminded of its obligations under the PFA in respect of insurance and is requested to provide information to Gavi on the steps it has taken in this regard.

Signed by,

Hind A. Thath

On behalf of Gavi Hind Khatib-Othman Managing Director, Country Programmes 22 December 2017